FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents

FDA approves Novartis’ Cosentyx to treat arthritis in children and adolescents

Source: 
Pharmaceutical Business Review
snippet: 

Novartis has received the US Food and Drug Administration (FDA) approval for its Cosentyx (secukinumab) to treat children and adolescents with enthesitis-related arthritis and psoriatic arthritis